Doctor consulting male patient, working on diagnostic examination on men's health disease or mental illness, while writing on prescription record information document in clinic or hospital office

Clinical Trials

Karyopharm-Sponsored Trials

STOMP Study in patients with relapsed/refractory multiple myeloma

STOMP is a Phase 1b/2 study evaluating selinexor and low-dose dexamethasone in combination with one of several standard approved therapies, including Revlimid® (lenalidomide), Pomalyst® (pomalidomide), Velcade® (bortezomib), Kyprolis® (carfilzomib), or Darzalex® (daratumumab), in patients with relapsed or refractory multiple myeloma. Additionally, a new arm to this study was added in 2018 to study the combination of selinexor and Revlimid® in newly diagnosed patients with multiple myeloma.  

Please visit clinicaltrials.gov for more information about this study


BOSTON Study in patients with relapsed/refractory multiple myeloma

BOSTON is a Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study that will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade®) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with relapsed / refractory multiple myeloma who have received 1 to 3 prior anti-multiple myeloma (MM) regimens.

Velcade® plus low-dose dexamethasone is a standard therapy for previously treated multiple myeloma that is given by injection two times a week. Unlike other drugs used to treat multiple myeloma, selinexor is taken orally.

Patients enrolled in the BOSTON study will receive either Velcade® plus low-dose dexamethasone (standard therapy given on the recommended schedule) or selinexor plus standard therapy taken one time per week.

Please visit clinicaltrials.gov for more information about this study


SADAL Study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.

Please visit clinicaltrials.gov for more information about this study


SEAL Study in patients with advanced unresectable dedifferentiated liposarcoma

SEAL is a Phase 3 randomized, multicenter, double-blind, placebo-controlled study evaluating selinexor in patients with advanced unresectable dedifferentiated liposarcoma.

Please visit clinicaltrials.gov for more information about this study


SIENDO Study in patients with endometrial cancer

SIENDO is a Phase 3 study evaluating once weekly selinexor as a maintenance therapy versus placebo in patients with endometrial cancer after first- or second-line chemotherapy.

Please visit clinicaltrials.gov for more information about this study


Investigator-Sponsored Trials

Often-times, clinical studies are initiated and managed by non-pharmaceutical company researchers, including individual physician investigators, institutions, or collaborative study groups.

Below is a list of ongoing investigator-sponsored trials studying Karyopharm’s investigational medicines in a host of different disease settings:

Multiple Myeloma

Phase II randomized, multicenter, comparator study of KPT-330, Cyclophosphamide and Prednisolone to assess progression-free survival compared to historic control data in R/R Multiple Myeloma

Indication: Multiple Myeloma

An Open-label, Multicenter, Phase 2 trial of selinexor plus bortezomib and daratumumab for the treatment of patients with R/R multiple myeloma

Indication: Multiple Myeloma

Phase I Study of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Indication: Multiple Myeloma

Phase I/II Study of Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Indication: Multiple Myeloma

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)

Indication: Multiple Myeloma


Acute Myeloid Leukemia (AML) & Myelodysplastic Syndromes (MDS)

An Investigator Sponsored Phase I Trial of Selinexor (KPT-330) plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Indication: AML

Selinexor With Induction, Consolidation, and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia

Indication: AML

Randomized Phase II Multicenter Study with a Safety Run-In to Assess the Tolerability and Efficacy of the Addition of Oral Selinexor (KPT-330) to Standard Induction Therapy in AML and High Risk MDS ≥ 66 years

Indication: AML, MDS


Lymphoma

Phase I Study of Selinexor Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Indication: DLBCL

Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Indication: BCL

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Indication: CLL, NHL

Phase Ib/II Study of Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B-cell Non-Hodgkin Lymphoma

Indication: NHL

Phase I Study of KPT330 in Asian Patients with Advanced or Metastatic Solid Tumor Malignancies

Indication: Solids, Lymphoma


Solid Tumors

A Randomized Phase III Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Indication: Endometrial

Phase IB Study of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies

Indication: Solids

Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

Indication: STS

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Indication: Head/Neck

Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer

indication: Pancreatic

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Indication: NSCLC

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy (SELECT)

Indication: Thymoma/TET

Phase II Study of Selinexor (KPT-330) in Patients with Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy

Indication: Thymoma/TET


Pediatric

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Indication: Pediatric AML

Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Indication: Pediatric Solids

ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.  On this website you will find more detailed information about specific clinical studies being conducted by Karyopharm, our development partners, and by independent investigators.

You can easily search for specific studies by entering the search terms “selinexor”, “eltanexor” “verdinexor” or “KPT-9274” from the website’s landing page / “Find a Study” section.